Coronavirus

Binding interface of electrostatic interactions have been recognized as an important factor for protein-protein recognition.

A protein subunit vaccine candidate for COVID-19 demonstrated safety and immunogenicity in a phase 1, placebo-controlled, dose escalation trial.

Findings may aid in understanding mechanisms by which drug molecules mitigate viral infections.

A syndemic association between the two infections may have an increasing impact on affected people and communities.

Findings are now being used to examine whether individuals with a history of brain trauma are more susceptible to the virus.

The company is reporting a reduced transmission after the first and second doses. However, questions are arising on the data around these claims and Switzerland declined to approve the vaccine.

A study's findings could and should shape vaccine distribution, the authors say.

Treatment shows promise for patients whose lungs are so injured that a ventilator is unable to deliver enough oxygen.

Molecular profiling of SARS-CoV-2-infected cell lines revealed pathways co-opted by the virus.

New preliminary phase 3 data show the two-dose vaccine may even hold benefit for single-dose use.

Investigators plan to partner with testing facilities at the University to distribute the device to students.

Adherence to nonpharmaceutical interventions such as staying home and avoiding eating in restaurants dropped during the pandemic, while use of face masks increased, according to a new report.

Patients with gastrointestinal tract problems may be susceptible to more severe disease and symptoms from the coronavirus.

Concerns are being raised for COVID-19 and the potential impact on HIV, tuberculosis, and malaria in low-income and middle-income countries. A team of researchers recently addressed this issue with a modeling study.

The world is closing in on 100 million total vaccine doses administered.

Cohort data shows 87% of infants born to mothers with asymptomatic or symptomatic COVID-19 have developed antibodies at birth.

A video breakdown of the past week's developments and news in leading vaccine candidates.

Investigators tested bamlanivimab monotherapy as well as in combination with etesevimab.

In the most recent trials of tocilizumab for COVID-19, patients with moderate illness benefited but survival rate of severely ill did not improve or worsened.

A discussion surrounding how environmental and behavioral factors can lower immune system responses.

The data from this study has stimulated international efforts exploring the use of the therapy for SARS-CoV-2.

Pre-existing high cholesterol levels have been associated with increased risk for severe COVID-19.

The to-be-reviewed assessment of real-world vaccine recipients suggests 51% greater efficacy with BNT162b2 after 13-24 days.

The European Medicines Agency announced today it has recommended granting a commercial marketing authorization (CMA) to the company for its vaccine.

Previous studies have linked psychiatric disorders in general to an increased risk of dying from the virus.

Data for its phase 3 trial shows differing levels of protection for moderate to severe disease depending on the geographic region.

The findings accompany news that the company is working on new vaccines to address more transmissible SARS-CoV-2 variants.

The US Centers for Disease Control and Prevention shares a similar outlook with the organization.

T cells are part of the immune system and play an important part in the body's protection against viral infections.

Recombination is proposed to be critical for coronavirus diversity and emergence of the SARS-CoV-2 variant.